
pm et
summari lead manufactur gener pharmaceut produc broad rang drug
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
see
rais target
line peer ep
estim set ep
estim although see sale
continu pressur gener price
eros like mid- high-singl digit
lower epipen sale million
encourag potenti
launch gener advair name wixela
june respond fda inquiri
also see potenti first
biosimilar launch neulasta
gener pegfilgrastim june
risk assess reflect risk inher gener
pharmaceut busi includ need
approv legal challeng brand patent
howev risk off-set wide
divers gener portfolio well promis brand
drug busi believ also acquisit merck
may ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor profil laboratori lead manufactur gener pharmaceut product
finish tablet capsul powder dosag form gener drug chemic equival brand
drug market patent expir primari product typic gener sold price
significantli compar brand product
market product throughout world gener divis market
gener primarili solid oral dose drug encompass wide varieti therapeut categori
gener extended-releas drug udl laboratori largest re-packag drug unit
dose format use primarili hospit nurs home similar set
india-bas matrix laboratori subsidiari manufactur activ pharmaceut
ingredi api use product well third parti matrix rank one largest
api produc world matrix also offer finish dose drug product
impact major develop octob acquir gener drug busi german
drugmak merck kgaa refer merck gener market sever hundr product
oper strong gener market exposur franc itali japan canada australia
also acquir dey produc brand specialti respiratori allergi drug merck kgaa
dey product epipen auto-injector treatment allerg reaction duoneb nebul
treatment copd april suppli auto-injector reach
patent litig settlement teva pharmaceut delay latter enter
epipen market earlier certain circumst
septemb acquir bionich pharma anoth maker inject drug decemb
acquir right produc gener version glaxosmithkin advair asthma drug
decemb acquir agila specialti indian maker gener inject billion
cash see potenti signific strateg benefit agila doubl busi higher
margin inject expand posit brazil emerg market
corpor strategi key object success integr merck gener capit
compani strength global reach vertic integr also plan focu
difficult-to-develop gener specialti pharmaceut well achiev greater economi scale
manufactur compani also seek first gener firm penetr new
market captur new product opportun obtain first-to-fil statu
exclus
market profil world-wide gener drug market estim billion
account global market boost rise demand inexpens gener
throughout world benefit larg number brand drug recent lost patent
protect unbrand brand gener account prescript dispens
 repres total pharmaceut sale dollar accord im
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
still think long-term prospect
remain one widest-margin
industri prospect enhanc
demograph growth elderli
account industri sale
new drug discoveri howev
number new molecular entiti approv
declin robust approv
sinc record
approv follow robust approv
approv
 pharmaceut index
declin versu rise
composit index year-to-d
juli pharmaceut index
declin vs rise
fundament outlook pharmaceut
sub-industri next month posit
top-lin pressur patent expir
mani top-sel drug bottom
anticip modest sale increas
follow growth see
modest advers impact foreign exchang
follow firm
 dollar late also see
expand sale new innov drug
therapi margin improv accru
cost restructur merger synergi ep
comparison also benefit common
see afford act
continu neg affect industri
margin see benefit includ improv
sale demand signific expans
insur popul accord
depart human servic
insur sinc law enact
howev presid trump republican
made effort repeal replac
arr uncertain compon
surviv particularli individu
mandat medicaid expans may
hous repres pass
ahca would result million
peopl uninsur compar
june senat unveil healthcar
plan better reconcili act
bcra howev senat yet vote
bill cbo estim million
peopl would uninsur compar
hous senat plan would
elimin individu mandat phase
medicaid expans
despit advers effect patent expir
regulatori pressur high drug price
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
respons public
affair \naviat medic administr area two publicli
trade compani tenur play integr role guid sunoco
work restructur compani busi portfolio revit
perform cultur previous zeleni execut vice presid
administr servic caremark rx led human resourc
commun public relat intern administr function prior
sale
et cfra keep hold opinion share nv
lower target peer
forward ep estim ep vs
estim lower ep estim
sale rose growth forecast
environ lower sale guidanc
declin epipen sale delay launch two
highli anticip gener advair copaxon expect
lower target peer
ep estim lower ep
ep vs estim sale aid
acquisit rose expect epipen sale fell competit
sale gener epipen sale account less
sale believ gener epipen account
market see increas throughout year separ
receiv non-approv complet respons letter gener advair /jeffrey
 announc appoint daniel gallagh chief legal
offic join compani april join
patomak global partner presid nov
oct gallagh serv commission secur
analyst research note compani news
rais target line peer
ep estim set ep estim
although see sale continu pressur gener price eros
like mid- high-singl digit lower epipen sale
million encourag potenti launch gener
advair name wixela june respond fda inquiri also
see potenti first biosimilar launch
neulasta gener pegfilgrastim june fda action date
 board director announc non-execut director
cameron retir board year servic
effect annual gener meet sharehold board
also announc nomin paulin van der meer mohr candid
elect board annual gener meet
et cfra keep hold opinion share
keep target in-lin peer
forward ep estim ep vs
view lower ep estim sale gener
price eros lower epipen sale cannib gener
epipen higher govern rebat fell european sale aid
meda deal rose see stronger driven gener copaxon sale
week end oct gener copaxon market share
new rx total rx see share rise /jeffrey loo cfa
presid rajiv malik identifi target
expand lawsuit brought forth variou state attorney gener alleg
price collus gener drug firm first time investig
name execut target probe expand firm
six state found evid price fix part
employe fulli stand behind mr malik lawsuit
overhang share sinc late last year believ
expand probe continu advers impact share /jeffrey loo
lower target peer
ep estim also lower
follow eu approv gener copaxon
also receiv fda approv gener copaxon oct see
continu challeng teva note on-going price pressur declin
copaxon sale particularli earlier-than-expect gener approv
version see asset sale help pay debt last month teva
agre sell women health unit paragard /jeffrey loo cfa
et cfra keep hold opinion share nv
rais target in-lin peer
forward ep estim fda approv gener
version teva pharmaceut teva multipl sclerosi drug
copaxon may also elig
exclus dose surpris fda action
anticip approv say begin ship
immin capoxon gener sale
believ particularli grant exclus gain
 announc appoint denni zeleni chief human relat
offic corpor realm zeleni serv senior vice presid
chief human resourc offic sunoco inc sunoco logist partner
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
